natgillin/translations-raw huggingface dataset:
Patients with mild-to-moderate hepatic insufficiency due to cirrhosis will require a dose reduction of indinavir due to decreased metabolism of indinavir (see section 4.2). 
U bolesnika s blagom do umjerenom insuficijencijom jetre koja je posljedica ciroze potrebno je sniziti dozu indinavira zbog smanjenog metabolizma indinavira (vidjeti dio 4.2).
 atorvastatin concentration Atorvastatin is less dependent on CYP3A4 for metabolism than lovastatin or simvastatin 
Metabolizam atorvastatina manje ovisi o CYP3A4 nego metabolizam lovastatina ili simvastatina.
increases in MCV, decreases in neutrophils increased spontaneous bleeding in patients with haemophilia, anemia including acute haemolytic anaemia, thrombocytopenia (see section 4.4). 
povećanje srednjeg staničnog volumena (MCV), smanjenje broja neutrofila pojačano spontano krvarenje u bolesnika s hemofilijom, anemija uključujući i akutnu hemolitičku anemiju, trombocitopenija (vidjeti dio 4.4)
Sulphamethoxazole/ Trimethoprim 800 mg/160 mg BID (Indinavir 400 mg QID) 
Sulfametoksazol/trimetoprim 800 mg/160 mg BID (indinavir 400 mg QID)
Interaction with indinavir/ritonavir not studied R-warfarin levels may be decreased leading to reduced anticoagulation due to induction of CYP1A2 and CYP2C9 by ritonavir. 
Koncentracije R-varfarina mogu biti snižene, što dovodi do smanjenja antikoagulacije zbog indukcije CYP1A2 i CYP2C9 ritonavirom.
myalgia myositis, rhabdomyolysis, increased CPK, osteonecrosis (see section 4.4), periarthritis. 
mialgija miozitis, rabdomioliza, povišene vrijednosti kreatin fosfokinaze, osteonekroza (vidjeti dio 4.4), periartritis
Autoimmune disorders (such as Graves' disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment. 
U uvjetima imunološke reaktivacije prijavljeni su i autoimuni poremećaji (kao što je Gravesova bolest i autoimuni hepatitis); međutim, prijavljeno vrijeme do pojave je različito i ti se događaji mogu javiti više mjeseci nakon uvođenja liječenja.
Amprenavir 600 mg BID AUC ↑ 64 % with 100 mg BID ritonavir alone (relative to amprenavir 1,200 mg BID alone). 
Amprenavir 600 mg BID AUC ↑ 64% kad se primjenjuje samo s ritonavirom u dozi od 100 mg BID (u odnosu na primjenu samo amprenavira u dozi od 1200 mg BID).
• kidney problems (including inflammation of the kidneys, kidney stones, or back pain with or without blood in your urine) 
• tegobe s bubrezima (uključujući upalu bubrega, bubrežne kamence ili bol u leđima koja može, ali i ne mora biti praćena krvlju u mokraći)
If co-administered with ritonavir, CRIXIVAN may be administered with or without food. 
Ako se primjenjuje istodobno s ritonavirom, CRIXIVAN se može uzimati s hranom ili bez nje.
The AUC and peak plasma concentrations were generally similar to those previously observed in HIV-infected adults receiving the recommended dose of 800 mg every 8 hours; it should be observed that the plasma concentrations 8 hours post dose were lower. 
AUC i vršna koncentracija u plazmi u načelu su bili podjednaki onima prethodno primijećenima u odraslih bolesnika zaraženih HIV-om koji su primali preporučenu dozu od 800 mg svakih 8 sati.
In HIV-infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. 
U bolesnika zaraženih virusom HIV-a s teškom imunodeficijencijom u trenutku uvođenja kombinirane antiretrovirusne terapije može se razviti upalna reakcija na asimptomatske ili rezidualne oportunističke infekcije.
Patients with mild-to-moderate hepatic insufficiency and clinical evidence of cirrhosis had evidence of decreased metabolism of indinavir resulting in approximately 60 % higher mean AUC following a 400-mg dose. 
U bolesnika s blagom do umjerenom insuficijencijom jetre i kliničkim dokazima ciroze zabilježen je smanjen metabolizam indinavira, što je nakon primjene doze od 400 mg dovelo povišenja srednjeg AUC-a za približno 60%.
In this open label nonrandomized single arm study, patients were treated with stavudine and lamivudine plus indinavir/ritonavir 400/100 mg every 12 hours. 
U tom otvorenom, nerandomiziranom ispitivanju s jednom skupinom bolesnici su liječeni stavudinom i lamivudinom u kombinaciji s indinavirom/ritonavirom u dozi od 400/100 mg svakih 12 sati.
Clinical adverse reactions reported by the investigators as possibly, probably, or definitely related to CRIXIVAN in  5 % of patients treated with CRIXIVAN monotherapy or in combination with NRTI(s) (n = 309) for 24 weeks are listed below. 
U nastavku su navedene kliničke nuspojave za koje su ispitivači procijenili da su možda, vjerojatno ili sigurno povezane s primjenom lijeka CRIXIVAN, u ≥ 5% bolesnika liječenih lijekom CRIXIVAN u monoterapiji ili u kombinaciji s jednim ili više NRTI-ja (n = 309) tijekom 24 tjedna.
• phenobarbital, phenytoin, carbamazepine, divalproex, lamotrigine - medicines used to treat fits (epilepsy) 
• fenobarbital, fenitoin, karbamazepin, divalproeks, lamotrigin - lijekovi za liječenje napadaja
Indinavir inhibits CYP3A4 and as a result is expected to markedly increase the plasma concentrations of these HMG-CoA reductase inhibitors, which are highly dependent on CYP3A4 metabolism. 
Indinavir inhibira CYP3A4 pa se očekuje da bi mogao značajno povisiti plazmatske koncentracije ovih inhibitora HMG-CoA reduktaze koji uvelike ovise o metabolizmu posredovanom CYP3A4.
In patients with mild-to-moderate hepatic impairment due to cirrhosis, the dose of indinavir should be reduced to 600 mg every 8 hours. 
U bolesnika s blagim do umjerenim oštećenjem funkcije jetre koje je posljedica ciroze, dozu indinavira treba smanjiti na 600 mg svakih 8 sati.
Interactions and dose recommendations with other medical products - INDINAVIR BOOSTED WITH RITONAVIR. 
Tablica 2. Interakcije i preporučene doze kod primjene s drugim lijekovima - INDINAVIR POJAČAN RITONAVIROM.
Cyclosporine A (CsA) levels markedly increase in patients on PIs, including indinavir. 
Koncentracije ciklosporina A (CsA) značajno su povišene u bolesnika koji primaju inhibitore proteaze, uključujući indinavir.
When to take 
Kada uzeti lijek
Indinavir alone or in combination with nucleoside analogues (zidovudine/stavudine and lamivudine) has been shown to delay clinical progression rate compared with nucleoside analogues and to provide a sustained effect on viral load and CD4 count. 
Pokazalo se da indinavir primijenjen sam ili u kombinaciji s nukleozidnim analozima (zidovudin/stavudin i lamivudin) usporava kliničku progresiju u odnosu na nukleozidne analoge te ostvaruje održan učinak na virusno opterećenje i broj CD4 stanica.
IMMUNOSUPPRESSIVES Cyclosporine A (Indinavir/ritonavir 800/100 BID) 
Ciklosporin A (indinavir/ritonavir 800/100 BID)
Ritonavir oral solution should not be coadministered with amprenavir oral solution to children due to the risk of toxicity from excipients in the two formulations. 
U djece se ritonavir oralna otopina ne smije primjenjivati istodobno s amprenavir oralnom otopinom zbog rizika od toksičnosti izazvane pomoćnim tvarima u tim pripravcima.
Indinavir AUC: ↔ 
AUC indinavira: ↔
isolated asymptomatic hyperbilirubinaemia, increased ALT and AST 
izolirana asimptomatska hiperbilirubinemija, povišene vrijednosti ALT-a i AST-a poremećaj funkcije jetre
Rifabutin AUC: ↑ 173 % Rifabutin Cmin: ↑ 244 % (Relative to rifabutin 300 mg QD alone) 
AUC rifabutina: ↑ 173% Cmin rifabutina: ↑ 244% (u odnosu na primjenu samo rifabutina u dozi od 300 mg QD)
Loratidine 
Loratadin
Interaction not studied 
Interakcija nije ispitana
Mean urinary excretion of unchanged medicinal product following single dose administration in the fasted state was 10.4 % following a 700-mg dose, and 12.0 % following a 1,000-mg dose. 
Nakon primjene jedne doze od 700 mg natašte mokraćom se u nepromijenjenom obliku izlučilo prosječno 10,4% lijeka, a nakon jedne doze od 1000 mg natašte prosječno 12,0% lijeka.
Ritonavir increases the serum levels of amprenavir as a result of CYP3A4 inhibition. 
Ritonavir povisuje koncentracije amprenavira u serumu zbog inhibicije CYP3A4.
In HIV-infected paediatric patients, the pharmacokinetic parameters of indinavir in apple sauce were: AUC0-8hr of 26,980 nM*h; peak plasma concentration of 13,711 nM; and plasma concentration at 8 hours post dose of 146 nM. 
U pedijatrijskih bolesnika zaraženih HIV-om farmakokinetički parametri indinavira u jabučnom soku bili su: AUC0-8h = 26 980 nM*h; vršna koncentracija u plazmi = 13 711 nM; koncentracija u plazmi 8 sati nakon primjene doze = 146 nM.
• kidney problems such as kidney infection, worsening or loss of kidney function 
• tegobe s bubrezima, poput infekcije bubrega, pogoršanja ili gubitka funkcije bubrega • bol i poteškoće pri pomicanju ramena.
Rifabutin AUC*: ↑ 54 % Rifabutin Cmin*: ↑ 99 % (*Relative to rifabutin 300 mg QD alone. 
AUC* rifabutina: ↑ 54% Cmin* rifabutina: ↑ 99% (*u odnosu na primjenu samo rifabutina u dozi od 300 mg QD.
Interaction with indinavir/ritonavir Not studied, combined administrations are expected to significantly increase concentrations of midazolam, particularly when midazolam is given orally (CYP3A4 inhibition). 
Interakcija s indinavirom/ritonavirom nije ispitivana, ali se očekuje da će kombinirana primjena dovesti do značajnih povišenja koncentracija midazolama, naročito kad se midazolam primjenjuje peroralno (inhibicija CYP3A4).
Indinavir AUC:  
AUC indinavira: 
The metabolism of indinavir is mediated by the cytochrome P450 enzyme CYP3A4. 
Metabolizam indinavira posredovan je enzimom CYP3A4 citokroma P450.
- rifampicin - an antibiotic used to treat infections - cisapride - used for gut problems - amiodarone - used for heart rhythm problems - pimozide - used for some mental health problems - lovastatin or simvastatin - used to lower cholesterol - St. John's wort (Hypericum perforatum) - a herbal medicine used for depression - ergot tartramine (with or without caffeine) - used for migraines - astemizole or terfenadine - antihistamines used for hay fever and other allergies - quetiapine - used for some mental illnesses such as schizophrenia, bipolar disorder and major depressive disorder - alprazolam, triazolam and midazolam (by mouth) - used to make you calmer or help you sleep. 
- pimozid - koristi se za neke tegobe s psihičkim zdravljem - lovastatin ili simvastatin - koriste se za snižavanje kolesterola - gospinu travu (Hypericum perforatum) - biljni lijek koji se koristi za depresiju - ergot tartramin (s kofeinom ili bez njega) - koristi se za migrenu - astemizol ili terfenadin - antihistaminici koji se koriste za liječenje peludne groznice i drugih alergija - kvetiapin - koristi se za liječenje psihičkih bolesti poput shizofrenije, bipolarnog poremećaja te velikog depresivnog poremećaja - alprazolam, triazolam i midazolam (kroz usta) - koriste se za umirenje ili da lakše zaspete
Diltiazem AUC0-24hr:  43 % Indinavir/ritonavir AUCs:  
AUC0-24h diltiazema:  43% AUC indinavira/ritonavira: 
Caution must also be exercised if indinavir is used concurrently with atorvastatin. 
Oprez je nužan i ako se indinavir primjenjuje istodobno s atorvastatinom.
 dihydropyridine calcium channel blocker concentration 
 koncentracija dihidropiridinskih blokatora kalcijevih kanala
Dose increases of indinavir/ritonavir when given in combination with efavirenz have not been studied. 
Nisu ispitivana povećanja doze indinavira/ritonavira kod istodobne primjene s efavirenzom.
Due to CYP3A inhibition by indinavir, concentrations of quetiapine are expected to increase. 
Zbog inhibicije CYP3A indinavirom očekuje se povišenje koncentracija kvetiapina.
Inhibition of CYP3A4 by both CRIXIVAN and ritonavir could result in elevated plasma concentrations of these medicines, potentially causing serious or life-threatening reactions. 
Inhibicija CYP3A4 koju uzrokuju i CRIXIVAN i ritonavir može dovesti do povišenih koncentracija tih lijekova u plazmi i tako potencijalno izazvati ozbiljne ili po život opasne reakcije.
Evaluation may consist of urinalysis, serum BUN and creatinine, and ultrasound of the bladder and kidneys. 
Procjena može obuhvatiti analizu urina, dušika iz ureje u krvi i kreatinin u serumu te ultrazvuk mokraćnog mjehura i bubrega.
Therefore coadministration is not recommended. 
Stoga se istodobna primjena ne preporučuje.
Desiccant should not be swallowed. 
Sredstvo za sušenje se ne smije progutati.
A dose reduction of indinavir to 600 mg every 8 hours should be considered when administering itraconazole or ketoconazole concurrently (see section 4.5). 
Pri istodobnoj primjeni itrakonazola ili ketokonazola treba razmotriti smanjenje doze indinavira na 600 mg svakih 8 sati (vidjeti dio 4.5).
Inhibition of CYP3A4 by both CRIXIVAN and ritonavir could result in elevated plasma concentrations of these medicines, potentially causing serious or life-threatening reactions (see section 4.5). 
Inhibicija CYP3A4 koju uzrokuju i CRIXIVAN i ritonavir može dovesti do povišenih koncentracija navedenih lijekova u plazmi i tako potencijalno izazvati ozbiljne ili po život opasne reakcije (vidjeti dio 4.5).
Zidovudine/Lamivudine 200/150 mg TID (Indinavir 800 mg TID) 
Zidovudin/lamivudin 200/150 mg TID (indinavir 800 mg TID)
There are no interaction data available on the coadministration of indinavir/ritonavir and amprenavir. 
Nema dostupnih podataka o interakciji kod istodobne primjene indinavira/ritonavira i amprenavira.
Characteristics in patients Pharmacokinetics of indinavir do not appear to be affected by race. 
Čini se da rasna pripadnost ne utječe na farmakokinetiku indinavira.
The most commonly reported symptoms were gastro-intestinal (e.g., nausea, vomiting, diarrhoea) and renal (e.g., nephrolithiasis, flank pain, haematuria). 
Najčešće prijavljeni simptomi bili su povezani s probavnim sustavom (npr. mučnina, povraćanje, proljev) i bubrezima (npr. nefrolitijaza, bol u slabinama, hematurija).
• CRIXIVAN - one 400 mg capsules (400 mg) - taken twice a day. 
• CRIXIVAN - jedna kapsula od 400 mg (400 mg) - dvaput na dan.
Nephrolithiasis occurred in approximately 10 % of patients treated with the recommended (unboosted) dose of CRIXIVAN in a pooled analysis of controlled clinical trials (see also below table and in section 4.4). 
U analizi objedinjenih podataka iz kontroliranih kliničkih ispitivanja nefrolitijaza se javila u otprilike 10% bolesnika liječenih preporučenom (nepojačanom) dozom lijeka CRIXIVAN (vidjeti i tablicu u nastavku teksta i dio 4.4).
Rosuvastatin AUC  2.08-fold Rosuvastatin Cmax  4.66-fold (Mechanism unknown) 
Ispitivanje interakcije s lopinavirom/ritonavirom + rosuvastatinom: AUC rosuvastatina  2,08 puta Cmax rosuvastatina  4,66 puta (mehanizam nije poznat)
ANTIDEPRESSANTS Trazodone 50 mg SD Ritonavir 200 mg BID 
Trazodon 50 mg SD Ritonavir 200 mg BID
Sixty-two patients completed the study to week 96. 
Ispitivanje u trajanju 96 tjedana su dovršila 62 bolesnika.
Amlodipine 5 mg QD (Indinavir/ritonavir 800/100 BID) 
Amlodipin 5 mg QD (indinavir/ritonavir 800/100 BID)
• Two 400 mg capsules (800 mg) - taken three times a day (every 8 hours). 
• dvije kapsule od 400 mg (800 mg) - triput na dan (svakih 8 sati).
Amlodipine AUC0-24hr:  80 % Indinavir/ritonavir AUCs:  
AUC0-24h amlodipina:  80% AUC indinavira/ritonavira: 
The crystals have not been associated with medicinal product -induced renal injury. 
Kristali se ne povezuju s oštećenjem bubrega prouzročenim primjenom lijeka.
Dose reduction of CRIXIVAN to 600 mg every 8 hours should be considered. 
Treba razmotriti smanjenje doze lijeka CRIXIVAN na 600 mg svakih 8 sati.
• allergic reactions - signs include itchy skin, redness of the skin, ‘wheals' or ‘hives', swelling of the face, lips, tongue or throat and difficulty breathing. 
• alergijske reakcije - znakovi uključuju svrbež kože, crvenilo kože, koprivnjaču, oticanje lica,
CALCIUM CHANNEL BLOCKERS Diltiazem 120 mg QD (Indinavir/ritonavir 800/100 BID) 
BLOKATORI KALCIJEVIH KANALA Diltiazem 120 mg QD (indinavir/ritonavir 800/100 BID)
• CRIXIVAN - two 200 mg capsules (400 mg) - taken twice a day. 
• CRIXIVAN - dvije kapsule od 200 mg (400 mg) - dvaput na dan.
ANTI-INFECTIVES Antiretrovirals Amprenavir 
Antiretrovirusni lijekovi Amprenavir
EU/1/96/024/001 180 hard capsules EU/1/96/024/002 270 hard capsules EU/1/96/024/003 360 hard capsules 
EU/1/96/024/001 180 tvrdih kapsula EU/1/96/024/002 270 tvrdih kapsula EU/1/96/024/003 360 tvrdih kapsula
Not known* new onset diabetes mellitus or hyperglycaemia, or exacerbation of pre-existing diabetes mellitus, hypertriglyceridaemia, hypercholesterolaemia. 
Poremećaji metabolizma i prehrane nepoznato* novonastala šećerna bolest ili hiperglikemija ili egzacerbacija postojeće šećerne bolesti, hipertrigliceridemija, hiperkolesterolemija
• dexamethasone - used to stop swelling (inflammation) 
• deksametazon - koristi se za zaustavljanje oticanja (upale)
• The capsules are printed with printing ink containing indigo carmine (E 132). 
• Oznaka na kapsuli otisnuta je tintom za označavanje koja sadrži boju indigo karmin (E132).
Safety in patients with impaired renal function has not been studied; however, less than 20 % of indinavir is excreted in the urine as unchanged medicinal product or metabolites (see section 4.4). 
Nije ispitivana sigurnost primjene u bolesnika s oštećenom funkcijom bubrega, međutim, manje od 20% indinavira se izlučuje mokraćom u neizmijenjenom obliku ili u obliku metabolita (vidjeti dio 4.4).
Pharmacokinetic analysis in one study was performed on nineteen of the patients, with a median (range) indinavir AUC 0-12hr, Cmax, and Cmin of 25,421 nM*h (21,489 - 36,236 nM*h), 5,758 nM (5,056 - 6,742 nM) and 239 (169 - 421 nM), respectively. 
U jednom je ispitivanju provedena farmakokinetička analiza u 19 bolesnika, pri čemu je medijan (raspon) vrijednosti farmakokinetičkih parametara indinavira bio sljedeći: AUC 0-12h 25 421 nM*h (21 489 - 36 236 nM*h), Cmax 5758 nM (5056 - 6742 nM), a Cmin 239 (169 - 421 nM).
An increase in hepatic weight occurred in rats treated with indinavir at doses  40 mg/kg/day and was accompanied by hepatocellular hypertrophy at doses  320 mg/kg/day. 
U štakora koji su primali doze indinavira ≥ 40 mg/kg na dan primijećen je porast težine jetre koji je kod primjene doza ≥ 320 mg/kg na dan bio popraćen hipertrofijom jetrenih stanica.
In another study, at week 16, the proportion of patients with plasma viral RNA below 400 copies/mL was 59 %; the mean increase in CD4 cell counts was 73 cells/mm 
U drugom je ispitivanju u 16. tjednu udio bolesnika s vrijednošću virusne RNK u plazmi manjom od 400 kopija/ml bio 59%; srednje povećanje broja CD4 stanica bilo je 73 stanice/mm
Indinavir with or without ritonavir should not be administered concurrently with medicinal products with narrow therapeutic windows and which are substrates of CYP3A4. 
Indinavir se u kombinaciji s ritonavirom ili bez njega ne smije primjenjivati istodobno s lijekovima koji imaju uzak terapijski raspon i koji su supstrati za CYP3A4.
Data from published studies suggest that CRIXIVAN 400 mg in combination with ritonavir 100 mg, both administered orally twice daily, may be an alternative dosing regimen. 
Podaci iz objavljenih ispitivanja pokazuju da kombinacija lijeka CRIXIVAN u dozi od 400 mg i ritonavira u dozi od 100 mg, primijenjena peroralno dvaput na dan, može poslužiti kao alternativni režim doziranja.
Safety in patients with impaired renal function has not been studied; however, less than 20 % of indinavir is excreted in the urine as unchanged medicinal product or metabolites (see section 4.2). 
Nije ispitivana sigurnost primjene u bolesnika s oštećenom funkcijom bubrega, međutim, manje od 20% indinavira se izlučuje kroz mokraću u neizmijenjenu obliku ili u obliku metabolita (vidjeti dio 4.2).
Cyclosporine A dose adjustments should be made according to measured cyclosporine A trough blood levels. 
A treba prilagoditi izmjerenim vrijednostima ciklosporina A u krvi.
The combination of rifampicin and CRIXIVAN with concomitant low-dose ritonavir is contraindicated (see section 4.3). 
Kombinacija rifampicina i lijeka CRIXIVAN uz istodobnu primjenu niske doze ritonavira je kontraindicirana (vidjeti dio 4.3).
Not studied, combined administration may result in increased warfarin levels. 
Nije ispitivano, kombinirana primjena može dovesti do povišenih koncentracija varfarina.
EU/1/96/024/004 90 hard capsules EU/1/96/024/005 180 hard capsules 
EU/1/96/024/004 90 tvrdih kapsula EU/1/96/024/005 180 tvrdih kapsula
Caution should be used with coadministration of CRIXIVAN and parenteral midazolam. 
Nužan je oprez pri istodobnoj primjeni lijeka CRIXIVAN i parenteralnog midazolama.
ANTICONVULSANTS Carbamazepine, phenobarbital phenytoin 
Karbamazepin, fenobarbital, fenitoin
• bone problems - signs include stiff joints, aches and pains, especially of the hip and difficulty moving. 
• tegobe s kostima - znakovi uključuju ukočene zglobove, bolove posebno u kuku te otežano kretanje.
HISTAMINE H2 ANTAGONIST Cimetidine 600 mg BID (Indinavir 400 mg SD) 
ANTAGONISTI HISTAMINSKIH H2 RECEPTORA Cimetidin 600 mg BID (indinavir 400 mg SD)
CALCIUM CHANNEL BLOCKERS Dihydropyridine: e.g., felodipine, nifedipine, nicardipine 
Dihidropiridini: npr. felodipin, nifedipin, nikardipin
CRIXIVAN with or without ritonavir should not be administered concurrently with amiodarone, terfenadine, cisapride, astemizole, quetiapine, alprazolam, triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5), pimozide, ergot derivatives, simvastatin or lovastatin (see section 4.4). 
CRIXIVAN se u kombinaciji s ritonavirom ili bez njega ne smije primjenjivati istodobno s amiodaronom, terfenadinom, cisapridom, astemizolom, kvetiapinom, alprazolamom, triazolamom, midazolamom primijenjenim peroralno (za mjere opreza pri parenteralnoj primjeni midazolama vidjeti dio 4.5), pimozidom, derivatima ergota, simvastatinom ili lovastatinom (vidjeti dio 4.4).
Interactions and dose recommendations with other medical products - UNBOOSTED INDINAVIR 
Tablica 1. Interakcije i preporučene doze kod primjene s drugim lijekovima - SAMO INDINAVIR
• Four 200 mg capsules (800 mg) - taken three times a day (every 8 hours). 
• četiri kapsule od 200 mg (800 mg) - triput na dan (svakih 8 sati).
Concurrent use of indinavir with herbal preparations containing St John's wort (Hypericum perforatum) is contraindicated (see section 4.5). 
Kontraindicirana je istodobna primjena indinavira s biljnim pripravcima koji sadrže gospinu travu (Hypericum perforatum) (vidjeti dio 4.5).
• feeling dizzy, weak or tired. 
• omaglica, slabost ili umor.
Indinavir levels may increase on stopping St. John's wort, and the dose of CRIXIVAN may need adjusting. 
Nakon prekida primjene gospine trave može doći do povišenja koncentracije indinavira pa će možda biti potrebno prilagoditi dozu lijeka CRIXIVAN.
What CRIXIVAN is used for 
Za što se koristi CRIXIVAN
In one study, at week 24, the proportion of patients with plasma viral RNA below 400 copies/mL was 60 %; the mean increase in CD4 cell counts was 242 cells/mm 
U jednom je ispitivanju u 24. tjednu udio bolesnika s vrijednošću virusne RNK u plazmi manjom od 400 kopija/ml bio 60%; srednje povećanje broja CD4 stanica bilo je 242 stanice/mm
3 years for HDPE bottles containing 90 and 180 hard capsules. 
3 godine za bočice od polietilena visoke gustoće s 90 i 180 tvrdih kapsula.
Norethindrone AUC: ↑ 26 % Norethindrone Cmin: ↑ 44 % 
AUC noretindrona: ↑ 26% Cmin noretindrona: ↑ 44%
Caution should be used with coadministration of CRIXIVAN with ritonavir and parenteral midazolam. 
Nužan je oprez pri istodobnoj primjeni lijeka CRIXIVAN s ritonavirom i parenteralnog midazolama.
Asymptomatic pyuria of unknown etiology was noted in 10.9 % (6/55) of paediatric patients who received CRIXIVAN. 
U 10,9% (6/55) pedijatrijskih bolesnika koji su primali CRIXIVAN zabilježena je asimptomatska piurija nepoznate etiologije.